Overview

Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus

Status:
Not yet recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

The DALICATH study aim to demonstrate the non-inferiority of a single administration of 1500 mg of dalbavancin compared with standard documented antibiotic therapy for 14 days according to national guidelines.

Phase:

Phase 3

Details

Lead Sponsor:

Centre Hospitalier Annecy Genevois

Collaborators:

ADVANZ PHARMA
APHP
Centre Hospitalier de Perigueux
Centre National de Reférence des Staphylocoques
French National Network of Clinical Research in Infectious Diseases (RENARCI)
Nantes University Hospital

Treatments:

Dalbavancin